HFpEF: from understanding the physiology to development of new treatments
Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.
Video navigation menu
Currently, there is no effective treatment for HFpEF. What has been tried and why did it fail? 0:25
Looking at the proposed underlying mechanisms of HFpEF: what may still work - hemodynamic targets 1:44
Molecular and cellular targets that may be of interest for novel HFpEF therapies 9:21
Ongoing trials evaluating various novel targets in HFpEF 19:52
Summary of potential mechanisms implicated in HFpEF and what that means for management of HFpEF patients 22:10
Educational information
This lecture by dr. Lam was part of a CME accredited symposium: Novel concepts and treatments of comorbidities in Heart Failure with Preserved Ejection Fraction held at ESC Heart Failure 2018 in Vienna.
Faculty
Prof. Carolyn Lam is a Senior Consultant of the National Heart Centre, Singapore and Professor of Duke-NUS Cardiovascular Academic Clinical Program. Dr. Lam also works as a cardiologist at the UMC Groningen, The Netherlands. Dr Lam’s clinical sub-specialty is heart failure, and she is recognized globally for her expertise in HFpEF. She also has expertise in women’s cardiovascular disease, hemodynamics, echocardiography, biomarkers and clinical trials.
Disclosures
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding
Funding for this educational program was provided by an unrestricted educational grant from Novartis and Novo Nordisk.
Share this page with your colleagues and friends: